sarepta duchenne muscular dystrophy

News

Sarepta Therapeutics to lay off 1-third of its workforce

Sarepta Therapeutics lays off one-third of workforce in drastic cost-cutting

The drastic cost-cutting move follows the deaths of two teenagers that forced the company to restrict usage of its gene therapy for Duchenne muscular dystrophy.

The Business Journals · 12h

Sarepta Therapeutics to lay off one-third of its workforce after gene therapy setback

Sarepta Therapeutics is facing a challenging period after the deaths of two patients who received its Columbus-invented gene therapy for Duchenne muscular dystrophy. Sarepta opens Columbus R&D center,

Bloomberg on MSN · 3h

Sarepta Says Another Patient Died After Receiving Gene Therapy

Sarepta Therapeutics Inc. said another patient has died from acute liver failure after receiving one of its gene therapies, putting additional pressure on the biotech company after the recent deaths of two teenage boys.

13hon MSN

Sarepta Stock Soars 30%. Why Layoffs and a ‘Black-Box’ Warning Are Good News.

Sarepta Therapeutics stock soared over 30% after the pharmaceutical company said it would lay off about 500 employees. It ...

MedPage Today on MSN9h

Duchenne Gene Therapy Will Undergo Changes After Patient Deaths

At the FDA's request, delandistrogene moxeparvovec (Elevidys), the only approved gene therapy for Duchenne muscular dystrophy ...

BioSpace15h

Sarepta Up 18% After Business Overhaul as Analysts Cautiously Optimistic

Sarepta Therapeutics appears to have right-sized itself after laying off over a third of its staff, announcing a significant ...

17h

Sarepta Therapeutics to cut 500 jobs amid restructuring

The company aims to focus on high-impact programmes to meet its 2027 financial obligations and support long-term viability.

13h

Sarepta Therapeutics' Reorganization Boosts Investor Confidence

Sarepta agrees to FDA's black box warning and announces major restructuring, including job cuts and cost-saving measures to ...

BioSpace1d

Sarepta Tags DMD Gene Therapy Elevidys With Black Box Warning, Axes 500 Staff

Following the death of two teenage patients with Duchenne muscular dystrophy following Elevidys treatment, Sarepta ...

19h

Sarepta Therapeutics: What's Happening With SRPT Stock?

The favorable market reaction indicates investor relief at management’s swift measures to rectify the company's worsening ...

Investing.com India1d

Sarepta Therapeutics stock soars after strategic restructuring plan unveiled

Investing.com -- Sarepta Therapeutics (NASDAQ: SRPT) stock soared 36% in after-hours trading Wednesday after the biotech company announced a major strategic restructuring plan designed to ensure ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results